Walking Sensation Study
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-95
SponsorUniversity of Florida
About this trial
The primary objective of this new line of research is to test whether augmenting sensory information from the legs, using Walkasins sensory neuroprosthesis, can enhance performance of a complex walking task in older adults with foot sensory impairment. The overarching hypothesis is that Walkasins will enhance the automaticity and reduce cognitive demand of walking in older adults with foot sensory impairments, as measured by reduced prefrontal activity, decreased dual-task costs, and lower gait variability.
Eligibility criteria
Qualifiers
Not having any significant existing medical conditions, historical health issues, or medications (outlined in the
Disqualifiers
age 65 - 95.
no severe high blood pressure (systolic < 180 mmHg and/or diastolic < 100 mmHg at rest).
no severe vision impairment: visual acuity ≥ 20/70 as determined by Snellen eye chart.
slow walking speed: preferred walking speed slower than 1.0 m/s over 10 meter.
Trial design
Treatments tested in this trial
- Active lower-limb neuroprosthesis
- Inactive lower-limb neuroprosthesis
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Florida
Lead sponsor
The Claude D. Pepper Older Americans Independence Centers
Collaborator
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov